Millions of eczema patients increasingly distrust the treatments medicine tells them to rely on. Matthew Zachary examines topical steroid withdrawal, chronic inflammation, patient distrust, and the healthcare incentives driving one of medicine’s fastest growing credibility crises

Hospitals blame insurers. Insurers blame hospitals. Patients finance the entire system through premiums, deductibles, debt, and confusion. Matthew Zachary examines the incentive structures, financial flows, and institutional dependencies that keep American healthcare expensive, opaque, and exhausting.

For 20 years, chemical reform promised protection. The system still allows widespread exposure while shifting risk to patients. This analysis explains how incentives, not science, determine what ends up in the products people use every day.

I paid $13.18 for a 90 day prescription through Cost Plus. Walgreens charged $30 with insurance. Same drug. Same supply. This is what PBMs do to pricing and why transparency exposes the middlemen.

Prior authorization persists because it works for the system that created it. This essay explains how cost control, risk management, and delay shape patient outcomes, why reform keeps falling short, and what must change to align financial incentives with timely care.

Only 0.2% of patients appeal insurance denials, yet 80% succeed. This article examines how even small increases in appeals could shift insurer behavior, raise costs, influence Wall Street expectations, and reshape the economics of American healthcare.

American healthcare delays care and denies treatment by design. Insurance rules, prior authorization, and administrative barriers control access to care, often slowing or blocking what doctors recommend and patients need.

A 30 year brain cancer survivor breaks down how insurance delays, denials, and red tape harm patients by design. This is not dysfunction. This is the business model.

When an insurer labels trigeminal nerve blocks investigational, patients may face brain surgery instead. This essay examines how coverage policy, coding decisions, and actuarial incentives shape care for trigeminal neuralgia and what must change to align patient protection with economic logic.

Sally Neely Nix manages chronic pain with nerve block injections. No opioids. Her insurer calls them experimental. So she built a policy brief and sent it to the CEO. While in extreme pain. Patients shouldn't have to become researchers to access care that works.

Mark Cuban walked into the Senate with spreadsheets and receipts. He called PBMs a cartel. He saved Medicare $2 billion. But math doesn't show up at town halls. Receipts don't vote. Here's the hole in his equation and an invitation to fix it.

Mark Cuban exposes PBM corruption and champions transparent drug pricing. He is right about generics. He is wrong about cash solving catastrophic care. A brain cancer survivor explains why $12 prescriptions and $960,000 transplants live in different universes.

In 2025, seven insurers generated $1.7 trillion in revenue and $54 billion in profit while covering 10 million fewer people. Premiums hit $26,993 for families. Public funding expanded. Consolidation deepened. The incentive structure driving American health insurance stands exposed.

UnitedHealth dropping Medicare Advantage plans for 600000 beneficiaries exposes a structural flaw in how private insurers manage public healthcare risk as costs from emergency care and specialty drugs accelerate faster than payment models can adjust.

A personal reflection on Gil Bashe’s Healing the Sick Care System and the growing revolt against insurance driven harm. From hospital memories to national accountability, this piece calls out who holds the wheel and why 2026 signals the rise of the patient voter bloc.

Blue Cross Blue Shield says insurers protect patients from high drug prices. The real world shows delays, denials, and blame shifting while patients wait, appeal, and deteriorate. A closer look at how insurers deflect responsibility in the drug pricing debate.

A new KFF poll shows prior authorization now ranks as the biggest burden in American healthcare. Delays and denials affect nearly half of insured adults, with severe mental, financial, and physical consequences. Patients across every plan agree.

Health insurers turned “medically necessary” into a denial weapon. This article breaks down how coverage policies, anonymous medical directors, and financial incentives allow insurers to override doctors and block cancer care, then outlines concrete fixes that could shut the system down.

After surviving brain cancer at 21, Matthew Zachary examines how modern healthcare policy repackages risk as freedom. From cash subsidies to math free promises, this essay exposes why consumer style healthcare fails the moment illness enters the room.

24 million Americans watched premiums double overnight. Now Trump plans to pressure insurers who banked $543 billion in profits over a decade. The solution? HSAs—which create new revenue streams for the same industry while shifting costs onto patients who already can't afford care. This isn't reform.